Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Treatment outcome among HIV positive and HIV negative TB patients in Chandigarh, India: A retrospective cohort study Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Prospective study analysing prevalence of XDR TB in Mumbai, India Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen? Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016
In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/GermanySource: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016